A phase II randomized, double-blind, parallel group, 26-week study of GSK-3 inhibitor tideglusib in Alzheimer's disease (ARGO trial)
del Ser, Teodoro, Lovestone, Simon, Boada-Rovira, Mercè, Dubois, Bruno, Hüll, Michael, Rinne, Juha, León, TeresaVolume:
9
Language:
english
Journal:
Alzheimer's & Dementia
DOI:
10.1016/j.jalz.2013.04.359
Date:
July, 2013
File:
PDF, 219 KB
english, 2013